Mucosis

Mucosis

Pioneering needle-free mucosal vaccines for natural and robust immunity.

Founded 2006 Venture round Total: $15.60M Biotechnology, Health Care

Mucosis B.V., founded in 2006, is a Dutch biotechnology company specializing in needle-free mucosal vaccines administered via the nose or mouth. Their flagship product, SynGEM®, an intranasal vaccine targeting respiratory syncytial virus infection, is based on the patented and validated Mimopath® technology. This technology aims to elicit a more natural immune response and provide broad protection, as evidenced in animal and human trials for their FluGEM® vaccine candidate. The company recently received a €5.70M Venture Round investment on January 20, 2016, with funding from BioGeneration Ventures and the Wellcome Trust, marking a significant milestone for their continued development. Mucosis operates within the Biotechnology and Health Care industries and is pioneering the field of needle-free mucosal vaccines, aiming to establish natural and robust immunity. Mucosis' dedication to innovation and their success in securing investments from key venture capitalists demonstrate the potential of their novel approach to vaccine development and their commitment to addressing critical healthcare challenges.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	€5.70M	2	BioGeneration Ventures, Wellcome Trust	20 Jan 2016
Venture Round	$6.90M	5	BioGeneration Ventures, NV NOM +3	29 Apr 2014
Series A	€3.00M	3	BioGeneration Ventures, NV NOM +1	10 Sep 2007

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

€5.70M

BioGeneration Ventures, Wellcome Trust

20 Jan 2016

Venture Round

$6.90M

BioGeneration Ventures, NV NOM +3

29 Apr 2014

Series A

€3.00M

BioGeneration Ventures, NV NOM +1

10 Sep 2007

FAQ About Mucosis

Pioneering needle-free mucosal vaccines for natural and robust immunity.

Mucosis was founded in 2006.

Mucosis operates in Biotechnology and Health Care. Its work centres on Vaccines, Intranasal delivery, Mucosal vaccines and Respiratory syncytial virus.

Mucosis has completed 3 funding rounds, raising a total of $15.60M. The latest funding stage is Venture round.

Top alternatives and competitors to Mucosis include Osivax, Misti, Vaxart, Inc., Vaxxas, X-Vax Technology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Mucosis and Osivax are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Mucosis

Funding Rounds & Investors (3)

Mucosis Alternatives & Competitors

FAQ About Mucosis